# EDGAR Filing Document

**Accession Number:** 0001809519
**File Stem:** 0001809519-26-000033
**Filing Date:** 2026-2
**Character Count:** 22823
**Document Hash:** 1e7200214c8a905c5ba34fd7676ed3f1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001809519-26-000033.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001809519-26-000033

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**REFERENCES 429**: 333-249069

**REFERENCES 429**: 333-254184

**REFERENCES 429**: 333-263118

**REFERENCES 429**: 333-270149

**REFERENCES 429**: 333-277511

**REFERENCES 429**: 333-285349

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260225

**EFFECTIVENESS DATE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GoodRx Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001809519
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 475104396
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293765
- **FILM NUMBER:** 26680844

**BUSINESS ADDRESS:**
- **STREET 1:** 2701 OLYMPIC BOULEVARD
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
- **BUSINESS PHONE:** (855) 268-2822

**MAIL ADDRESS:**
- **STREET 1:** 2701 OLYMPIC BOULEVARD
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404

**As filed with the Securities and Exchange Commission on February 25, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

**GoodRx Holdings, Inc.** 

**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **47-5104396** |
| **(State or other jurisdiction of**<br>**incorporation or organization)**<br>| **(I.R.S. Employer**<br>**Identification No.)**<br>|

---

**2701 Olympic Boulevard**

**Santa Monica, CA 90404** 

**(855) 268-2822** 

**(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)** 

**GoodRx Holdings, Inc. 2020 Incentive Award Plan** 

**GoodRx Holdings, Inc. 2020 Employee Stock Purchase Plan** 

**(Full title of the plans)** 

**Christopher McGinnis**

**Chief Financial Officer** 

**2701 Olympic Boulevard**

**Santa Monica, CA 90404** 

**(855) 268-2822** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Marc D. Jaffe** 

**Benjamin J. Cohen**

**Jenna Cooper** 

**Latham & Watkins LLP** 

**1271 Avenue of the Americas** 

**New York, NY 10020** 

**(212) 906-1200** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller

reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller

reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the

"Commission") for the purpose of registering an additional 31,525,813 shares of Class A common stock, par value $0.0001 per

share (the "Class A Common Stock"), of GoodRx Holdings, Inc. (the "Registrant"), issuable under the following employee

benefit plans for which registration statements of the Registrant on Form S-8 (<u>[File No. 333-249069](https://www.sec.gov/Archives/edgar/data/1809519/000119312520254694/d62083ds8.htm)</u>), Form S-8 (<u>[File No.](https://www.sec.gov/Archives/edgar/data/1809519/000119312521078119/d24916ds8.htm)</u> 

<u>[333-254184](https://www.sec.gov/Archives/edgar/data/1809519/000119312521078119/d24916ds8.htm)</u>), Form S-8 (<u>[File No. 333-263118](https://www.sec.gov/Archives/edgar/data/1809519/000119312522058736/d311674ds8.htm)</u>), Form S-8 (<u>[File No. 333-270149](https://www.sec.gov/Archives/edgar/data/1809519/000095017023005269/gdrx_s-8_2023.htm)</u>), Form S-8 (<u>[File No. 333-277511](https://www.sec.gov/Archives/edgar/data/1809519/000180951924000034/gdrxs-82024.htm)</u>) and Form S-8

(<u>[File No. 333-285349](https://www.sec.gov/Archives/edgar/data/1809519/000180951925000042/gdrxforms-8fy24.htm)</u>) are effective: (i) the GoodRx Holdings, Inc. 2020 Incentive Award Plan and (ii) the GoodRx Holdings,

Inc. 2020 Employee Stock Purchase Plan.

Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are

incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently

filed document, which is incorporated by reference herein or therein.

**Item 8. EXHIBITS.** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit**<br>**Number**<br>| <br>**Exhibit Description** | **Form** | **File** <br>**Number**<br>| **Filing** <br>**Date**<br>| **Exhibit** |<br>**Filed**<br>**Herewith**<br>|
| 4.1 | <u>[Amended and Restated Certificate of](https://www.sec.gov/Archives/edgar/data/1809519/000119312520256438/d35545dex31.htm)</u><br><u>[Incorporation](https://www.sec.gov/Archives/edgar/data/1809519/000119312520256438/d35545dex31.htm)</u><br>| 8-K | 001-39549 | 9-28-2020 | 3.1 |  |
| 4.2 | <u>[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/1809519/000119312520256438/d35545dex32.htm)</u> | 8-K | 001-39549 | 9-28-2020 | 3.2 |  |
| 4.3 | <u>[Form of Certificate of Class A Common](https://www.sec.gov/Archives/edgar/data/1809519/000119312520234662/d949310dex41.htm)</u><br><u>[Stock](https://www.sec.gov/Archives/edgar/data/1809519/000119312520234662/d949310dex41.htm)</u><br>| S-1/A | 333-248465 | 8-28-2020 | 4.1 |  |
| 5.1 | <u>[Opinion of Latham & Watkins LLP](exhibit51-opinionfy25sx8lw.htm)</u>  |  |  |  |  | X |
| 23.1 | <u>[Consent of PricewaterhouseCoopers LLP](exhibit231-fy25goodrxconse.htm)</u> |  |  |  |  | X |
| 23.2 | <u>[Consent of Latham & Watkins LLP](exhibit51-opinionfy25sx8lw.htm)</u><br><u>[(included in Exhibit 5.1)](exhibit51-opinionfy25sx8lw.htm)</u><br>|  |  |  |  | X |
| 24.1 | <u>[Power of Attorney](#i86c4d70ae36a4555ab1df794613b524f_10)</u> |  |  |  |  | X |
| 99.1 | <u>[GoodRx Holdings, Inc. 2020 Incentive](https://www.sec.gov/Archives/edgar/data/1809519/000119312520254694/d62083dex992.htm)</u><br><u>[Award Plan](https://www.sec.gov/Archives/edgar/data/1809519/000119312520254694/d62083dex992.htm)</u><br>| S-8 | 333-249069 | 9-25-2020 | 99.2 |  |
| 99.1.1 | <u>[Form of Option Agreement pursuant to](https://www.sec.gov/Archives/edgar/data/1809519/000119312520244628/d949310dex1031.htm)</u><br><u>[2020 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1809519/000119312520244628/d949310dex1031.htm)</u><br>| S-1/A | 333-248465 | 9-14-2020 | 10.3.1 |  |
| 99.1.2 | <u>[Form of Restricted Stock Unit Agreement](https://www.sec.gov/Archives/edgar/data/1809519/000119312520244628/d949310dex1032.htm)</u><br><u>[pursuant to 2020 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1809519/000119312520244628/d949310dex1032.htm)</u><br>| S-1/A | 333-248465 | 9-14-2020 | 10.3.2 |  |
| 99.1.5 | <u>[First Amendment to GoodRx Holdings, Inc.](https://www.sec.gov/Archives/edgar/data/1809519/000156459021027706/gdrx-ex101_63.htm)</u><br><u>[2020 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1809519/000156459021027706/gdrx-ex101_63.htm)</u><br>| 10-Q | 001-39549 | 5-13-2021 | 10.1 |  |
| 99.1.6 | <u>[Form of Director Deferred Cash Fees RSU](https://www.sec.gov/Archives/edgar/data/1809519/000180951924000032/ex10181formofdirectordefer.htm)</u><br><u>[Agreement](https://www.sec.gov/Archives/edgar/data/1809519/000180951924000032/ex10181formofdirectordefer.htm)</u><br>| 10-K | 001-39549 | 2-29-2024 | 10.18.1 |  |
| 99.1.7 | <u>[Form of Director Deferred RSU Agreement](https://www.sec.gov/Archives/edgar/data/1809519/000180951924000032/ex10182formofdirectordefer.htm)</u> | 10-K | 001-39549 | 2-29-2024 | 10.18.2 |  |
| 99.1.8 | <u>[Form of Option Agreement pursuant to](https://www.sec.gov/Archives/edgar/data/1809519/000180951925000143/exhibit101-goodrxxformofop.htm)</u><br><u>[2020 Incentive Award Plan (2025 Form)](https://www.sec.gov/Archives/edgar/data/1809519/000180951925000143/exhibit101-goodrxxformofop.htm)</u><br>| 10-Q | 001-39549 | 10.1 | 10.1 |  |
| 99.1.9 | <u>[Form of Restricted Stock Unit Agreement](https://www.sec.gov/Archives/edgar/data/1809519/000180951925000143/exhibit102-goodrxxformofrs.htm)</u><br><u>[pursuant to 2020 Incentive Award Plan](https://www.sec.gov/Archives/edgar/data/1809519/000180951925000143/exhibit102-goodrxxformofrs.htm)</u><br><u>[(2025 Form)](https://www.sec.gov/Archives/edgar/data/1809519/000180951925000143/exhibit102-goodrxxformofrs.htm)</u><br>| 10-Q | 001-39549 | 10.2 | 10.2 |  |
| 99.2 | <u>[GoodRx Holdings, Inc. 2020 Employee](https://www.sec.gov/Archives/edgar/data/1809519/000119312520244628/d949310dex104.htm)</u><br><u>[Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1809519/000119312520244628/d949310dex104.htm)</u><br>| S-1/A | 333-248465 | 9-14-2020 | 10.4 |  |
| 107.1 | <u>[Filing Fee Table](exfilingfees.htm)</u> |  |  |  |  | X |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to

believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on

its behalf by the undersigned, thereunto duly authorized, in the City of Santa Monica, State of California, on this 25<sup>th</sup> day of

February, 2026.

---

| | |
|:---|:---|
|  | **GOODRX HOLDINGS, INC.** |
| By: | /s/ Christopher McGinnis |
|  | Christopher McGinnis<br>Chief Financial Officer & Treasurer<br>|

---

**SIGNATURES AND POWER OF ATTORNEY** 

We, the undersigned officers and directors of GoodRx Holdings, Inc., hereby severally constitute and appoint Wendy Barnes and

Christopher McGinnis, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-

fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and

stead, and in any and all capacities, to sign this registration statement and any and all amendments (including post-effective

amendments) to this registration statement and all documents relating thereto, and to file the same, with all exhibits thereto, and

other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and

agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be

done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and

confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do

or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the

following persons in the capacities held on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Wendy Barnes | Chief Executive Officer & President | February 25, 2026 |
| Wendy Barnes | *(Principal Executive Officer)* |  |
| /s/ Christopher McGinnis | Chief Financial Officer & Treasurer | February 25, 2026 |
| Christopher McGinnis | *(Principal Financial Officer)* |  |
| /s/ Romin Nabiey | Chief Accounting Officer | February 25, 2026 |
| Romin Nabiey | *(Principal Accounting Officer)* |  |
| /s/ Trevor Bezdek | Co-Chairman of the Board | February 25, 2026 |
| Trevor Bezdek |  |  |
| /s/ Scott Wagner | Co-Chairman of the Board | February 25, 2026 |
| Scott Wagner |  |  |
| /s/ Christopher Adams | Director | February 25, 2026 |
| Christopher Adams |  |  |
| /s/ Ronald E. Bruehlman | Director | February 25, 2026 |
| Ronald E. Bruehlman |  |  |
| /s/ Ian T. Clark | Director | February 25, 2026 |
| Ian T. Clark |  |  |
| /s/ Dipanjan Deb | Director | February 25, 2026 |
| Dipanjan Deb |  |  |

---

---

| | | |
|:---|:---|:---|
| /s/ Douglas Hirsch | Director | February 25, 2026 |
| Douglas Hirsch |  |  |
| /s/ Kelly J. Kennedy | Director | February 25, 2026 |
| Kelly J. Kennedy |  |  |
| /s/ Gregory Mondre | Director | February 25, 2026 |
| Gregory Mondre |  |  |
| /s/ Agnes Rey-Giraud | Director | February 25, 2026 |
| Agnes Rey-Giraud |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **GoodRx Holdings, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Class A common stock; $0.0001 par value per share | Other | 31525813 | $2.35 | $74085660.55 | 0.0001381 | $10231.23 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $74085660.55  |  | $10231.23  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $10231.23  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) Amount to be Registered - In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. The amount registered consists of 31,525,813 shares of Class A Common Stock, par value $0.0001 per share (the "Class A Common Stock"), of GoodRx Holdings, Inc. (the "Registrant") that are issuable under the Registrant's 2020 Incentive Award Plan, as amended and the Registrant's 2020 Employee Stock Purchase Plan, as amended. (2) Proposed Maximum Offering Price per Unit - Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant's Class A common stock as reported on The Nasdaq Stock Market LLC on February 23, 2026. (3) Total Fee Offsets - The Registrant does not have any fee offsets.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![image_01a.jpg](image_01a.jpg) | 1271 Avenue of the Americas<br>New York, New York 10020-1401<br>Tel: +1.212.906.1200 Fax: +1.212.751.4864<br>www.lw.com<br>FIRM / AFFILIATE OFFICES<br>Austin Milan<br>Beijing Munich<br>Boston New York<br>Brussels Orange County<br>Century City Paris<br>Chicago Riyadh<br>Dubai San Diego<br>Düsseldorf San Francisco<br>Frankfurt Seoul<br>Hamburg Silicon Valley<br>Hong Kong Singapore<br>Houston Tel Aviv<br>London Tokyo<br>Los Angeles Washington, D.C.<br>Madrid<br>|

---

February 25, 2026

GoodRx Holdings, Inc.

2701 Olympic Boulevard

Santa Monica, CA 90404

Re:<u>Registration Statement on Form S-8 with respect to shares of Class A common</u> 

<u>stock of GoodRx Holdings, Inc.</u> 

To the addressee set forth above:

We have acted as special counsel to GoodRx Holdings, Inc., a Delaware corporation (the

"***Company***"), in connection with the preparation and filing by the Company on the date hereof with

the Securities and Exchange Commission (the "***Commission***") of a Registration Statement (the

"***Registration Statement***") on Form S-8 under the Securities Act of 1933, as amended (the "***Act***"),

relating to the issuance of up to 31,525,813 shares (the "***Shares***") of Class A common stock of the

Company, par value $0.0001 per share (the "***Class A Common Stock***"), which may be issued

pursuant to the Company's 2020 Incentive Award Plan (the "***2020 Plan***") and the Company's 2020

Employee Stock Purchase Plan (the "***2020 ESPP***"). This opinion is being furnished in connection

with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is

expressed herein as to any matter pertaining to the contents of the Registration Statement or

prospectuses forming a part thereof, other than as expressly stated herein with respect to the

issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have

considered appropriate for purposes of this letter. With your consent, we have relied upon the

foregoing and upon certificates and other assurances of officers of the Company and others as to

factual matters without having independently verified such factual matters. We are opining herein

only as to the General Corporation Law of the State of Delaware, as amended (the "***DGCL***"), and

we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that as of

the date hereof, when the Shares shall have been duly registered on the books of the transfer agent

**February 25, 2026**

**Page 2**

![image_01a.jpg](image_01a.jpg)

and registrar therefor in the name or on behalf of the recipients thereof, and have been issued by the

Company for legal consideration in excess of par value in the circumstances contemplated by the

2020 Plan and the 2020 ESPP, assuming in each case that the individual issuances, grants or awards

under the 2020 Plan and the 2020 ESPP are duly authorized by all necessary corporate action and

duly issued, granted or awarded and exercised in accordance with the requirements of law and the

2020 Plan and the 2020 ESPP (and the agreements duly adopted thereunder and in accordance

therewith), the issue and sale of the Shares will have been duly authorized by all necessary

corporate action of the Company, and such Shares will be validly issued, fully paid and non-

assessable. In rendering the foregoing opinion, we have assumed that the Company will comply

with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be

relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of

the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving

such consent, we do not thereby admit that we are in the category of persons whose consent is

required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Sincerely,

/s/ Latham & Watkins LLP

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of GoodRx Holdings, Inc. of our

report dated February 25, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting,

which appears in GoodRx Holdings, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

Los Angeles, California

February 25, 2026